There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acorda Therapeutics (ACOR – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) with bullish sentiments.

Acorda Therapeutics (ACOR)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acorda Therapeutics today and set a price target of $33. The company’s shares closed on Friday at $17.05.

Selvaraju observed:

“Valuation methodology, risks, and uncertainties. We currently ascribe $400M to AMPYRA and $1.2B to INBRIJA on a risk-adjusted net present value (rNPV) basis, using a 13% discount rate for INBRIJA along with a 12% discount rate for AMPYRA.”

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -15.7% and a 25.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Acorda Therapeutics is a Hold with an average price target of $24.17, representing a 41.8% upside. In a report issued on January 7, Cowen & Co. also maintained a Buy rating on the stock with a $30 price target.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.5% and a 37.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on Galmed Pharmaceuticals is a Strong Buy with an average price target of $34.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.